292 related articles for article (PubMed ID: 22142306)
1. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
Jensen JM; Scherer A; Wanke C; Bräutigam M; Bongiovanni S; Letzkus M; Staedtler F; Kehren J; Zuehlsdorf M; Schwarz T; Weichenthal M; Fölster-Holst R; Proksch E
Allergy; 2012 Mar; 67(3):413-23. PubMed ID: 22142306
[TBL] [Abstract][Full Text] [Related]
2. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions.
Grzanka A; Zebracka-Gala J; Rachowska R; Bozek A; Kowalska M; Jarzab J
Exp Dermatol; 2012 Mar; 21(3):184-8. PubMed ID: 22142393
[TBL] [Abstract][Full Text] [Related]
3. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis.
Jensen JM; Pfeiffer S; Witt M; Bräutigam M; Neumann C; Weichenthal M; Schwarz T; Fölster-Holst R; Proksch E
J Allergy Clin Immunol; 2009 May; 123(5):1124-33. PubMed ID: 19410693
[TBL] [Abstract][Full Text] [Related]
4. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
5. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
[TBL] [Abstract][Full Text] [Related]
6. Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids.
Jensen JM; Ahrens K; Meingassner J; Scherer A; Bräutigam M; Stütz A; Schwarz T; Fölster-Holst R; Harder J; Gläser R; Proksch E
Exp Dermatol; 2011 Oct; 20(10):783-8. PubMed ID: 21707760
[TBL] [Abstract][Full Text] [Related]
7. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis.
Frankel A; Sohn A; Patel RV; Lebwohl M
J Drugs Dermatol; 2011 Jun; 10(6):666-72. PubMed ID: 21637908
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T; Kapp A; Spergel J
Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
10. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
11. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
Kreuter A; Sommer A; Hyun J; Bräutigam M; Brockmeyer NH; Altmeyer P; Gambichler T
Arch Dermatol; 2006 Sep; 142(9):1138-43. PubMed ID: 16983001
[TBL] [Abstract][Full Text] [Related]
12. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.
Stuetz A; Baumann K; Grassberger M; Wolff K; Meingassner JG
Int Arch Allergy Immunol; 2006; 141(3):199-212. PubMed ID: 16926539
[TBL] [Abstract][Full Text] [Related]
13. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis.
Aschoff R; Schwanebeck U; Bräutigam M; Meurer M
Exp Dermatol; 2009 Jan; 18(1):24-9. PubMed ID: 18637133
[TBL] [Abstract][Full Text] [Related]
14. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial.
Bangert C; Strober BE; Cork M; Ortonne JP; Luger T; Bieber T; Ferguson A; Ecker RC; Kopp T; Weise-Riccardi S; Guettner A; Stingl G
Dermatology; 2011 Feb; 222(1):36-48. PubMed ID: 21150167
[TBL] [Abstract][Full Text] [Related]
15. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.
Papp K; Staab D; Harper J; Potter P; Puig L; Ortonne JP; Molloy S; Barbier N; Paul C;
Int J Dermatol; 2004 Dec; 43(12):978-83. PubMed ID: 15569038
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
17. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Grassberger M; Steinhoff M; Schneider D; Luger TA
Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
[TBL] [Abstract][Full Text] [Related]
18. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Gisondi P; Ellis CN; Girolomoni G
Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
[TBL] [Abstract][Full Text] [Related]
19. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment.
Simon D; Vassina E; Yousefi S; Braathen LR; Simon HU
Allergy; 2005 Jul; 60(7):944-51. PubMed ID: 15932386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
